CASI Pharmaceuticals (CASI) Expected to Announce Earnings on Monday

CASI Pharmaceuticals (NASDAQ:CASI) is expected to be announcing its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

CASI Pharmaceuticals Price Performance

Shares of CASI stock opened at $0.21 on Monday. The company has a market capitalization of $2.55 million, a P/E ratio of -0.07 and a beta of 0.91. The company’s 50-day simple moving average is $0.67 and its two-hundred day simple moving average is $1.13. CASI Pharmaceuticals has a one year low of $0.21 and a one year high of $3.09.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its holdings in CASI Pharmaceuticals by 2,013.3% during the third quarter. Bank of America Corp DE now owns 254,884 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 242,823 shares during the period. Woodline Partners LP lifted its holdings in CASI Pharmaceuticals by 64.9% in the first quarter. Woodline Partners LP now owns 164,365 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 64,675 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in CASI Pharmaceuticals in the 3rd quarter worth approximately $55,000. Hedge funds and other institutional investors own 22.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CASI Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CASI Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $4.00.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers.